亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Divi’s, Gland, Fidelity enter race to buy Orchid Pharma

firstwordpharmaMarch 04, 2019

Tag: Divi’s , Fidelity , Orchid Pharma , Gland

  • The Economic Times reported that Divi's Laboratories, Divi’s Laboratories Gland Celsus Bio Chemicals and Fidelity Trading Corporation have shown preliminary interest in taking over Orchid Pharma.

  • Other bidders keen to acquire the bulk cephalosporin drugmaker include financial investors Everstone, Piramal Capital, AION Capital, ART Capital and Finquest Group.

  • The news comes after the Chennai bench of the National Company Law Tribunal (NCLT) knocked back a proposal by Ingen Capital to take over Orchid Pharma after it failed to bring in the requisite money.

Register as Visitor to CPhI China 2019!

Previous:Pharma Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up

Next:Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service